Cargando…

Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade

The use of antibodies to target immune checkpoints, particularly PD-1/PD-L1, has made a profound impact in the field of cancer immunotherapy. Here, we identified KN035, an anti-PD-L1 nanobody that can strongly induce T-cell responses and inhibit tumor growth. The crystal structures of KN035 complexe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Fei, Wei, Hudie, Wang, Xiaoxiao, Bai, Yu, Wang, Pilin, Wu, Jiawei, Jiang, Xiaoyong, Wang, Yugang, Cai, Haiyan, Xu, Ting, Zhou, Aiwu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5341541/ https://www.ncbi.nlm.nih.gov/pubmed/28280600 http://dx.doi.org/10.1038/celldisc.2017.4

Ejemplares similares

Structural basis of the therapeutic anti-PD-L1 antibody atezolizumab
por: Zhang, Fei, et al.
Publicado: (2017)

Structural basis of a novel heterodimeric Fc for bispecific antibody production
por: Wei, Hudie, et al.
Publicado: (2017)

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
por: Wang, Xin, et al.
Publicado: (2019)

β-Glucan Combined With PD-1/PD-L1 Checkpoint Blockade for Immunotherapy in Patients With Advanced Cancer
por: Wang, Mengjie, et al.
Publicado: (2022)

Structural Basis of a Novel Agonistic Anti-OX40 Antibody
por: Zhang, Jing, et al.
Publicado: (2022)

Adipose PD-L1 Modulates PD-1/PD-L1 Checkpoint Blockade Immunotherapy Efficacy in Breast Cancer
por: Wu, Bogang, et al.
Publicado: (2018)

Immunotherapy of alveolar echinococcosis via PD‐1/PD‐L1 immune checkpoint blockade in mice
por: Wang, Junhua, et al.
Publicado: (2018)

Immune checkpoint blockade: the role of PD-1-PD-L axis in lymphoid malignancies
por: Ilcus, Cristina, et al.
Publicado: (2017)

Immune checkpoint expression and relationships to anti-PD-L1 immune checkpoint blockade cancer immunotherapy efficacy in aged versus young mice
por: Garcia, Myrna G., et al.
Publicado: (2022)

Nanobody-based CTLA4 inhibitors for immune checkpoint blockade therapy of canine cancer patients
por: Marable, Jonathan, et al.
Publicado: (2021)

A novel bispecific antibody for EGFR-directed blockade of the PD-1/PD-L1 immune checkpoint
por: Koopmans, Iris, et al.
Publicado: (2018)

Molecular Biomarkers of Response to PD-1/ PD-L1 Immune Checkpoint Blockade in Advanced Bladder Cancer
Publicado: (2021)

A Novel Computational Framework for Predicting the Survival of Cancer Patients With PD-1/PD-L1 Checkpoint Blockade Therapy
por: Su, Xiaofan, et al.
Publicado: (2022)

Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade
por: Lipson, Evan J., et al.
Publicado: (2017)

Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy
por: Lee, Ju Yeon, et al.
Publicado: (2016)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

Review and prospect of immune checkpoint blockade therapy represented by PD-1/PD-L1 in the treatment of clear cell renal cell carcinoma
por: GE, WENFEI, et al.
Publicado: (2023)

Seeing is believing: anti-PD-1/PD-L1 monoclonal antibodies in action for checkpoint blockade tumor immunotherapy
por: Tan, Shuguang, et al.
Publicado: (2016)

Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy
por: Ma, Weijie, et al.
Publicado: (2016)

Molecular Biomarkers of Response to PD-1/ PD-L1 Immune Checkpoint Blockade in Advanced Bladder Cancer(1)
Publicado: (2020)

Molecular Biomarkers of Response to PD-1/ PD-L1 Immune Checkpoint Blockade in Advanced Bladder Cancer(1)
por: Tu, Megan M., et al.
Publicado: (2019)

Immune Checkpoint Blockade Anti–PD-L1 as a Trigger for Autoimmune Polyendocrine Syndrome
por: Lanzolla, Giulia, et al.
Publicado: (2019)

Neutralization of PD-L2 is Essential for Overcoming Immune Checkpoint Blockade Resistance in Ovarian Cancer
por: Miao, Yu Rebecca, et al.
Publicado: (2021)

Niclosamide, an antihelmintic drug, enhances efficacy of PD-1/PD-L1 immune checkpoint blockade in non-small cell lung cancer
por: Luo, Fan, et al.
Publicado: (2019)

Blockade of dual immune checkpoint inhibitory signals with a CD47/PD-L1 bispecific antibody for cancer treatment
por: Wang, Rongjuan, et al.
Publicado: (2023)

Targeted Glucose or Glutamine Metabolic Therapy Combined With PD-1/PD-L1 Checkpoint Blockade Immunotherapy for the Treatment of Tumors - Mechanisms and Strategies
por: Ma, Guofeng, et al.
Publicado: (2021)

Macrophages facilitate tumor cell PD‐L1 expression via an IL‐1β‐centered loop to attenuate immune checkpoint blockade
por: Xu, Cheng, et al.
Publicado: (2023)

Structural basis of α(1A)-adrenergic receptor activation and recognition by an extracellular nanobody
por: Toyoda, Yosuke, et al.
Publicado: (2023)

Further investigation of blockade effects and binding affinities of selected natural compounds to immune checkpoint PD-1/PD-L1
por: Li, Huifang, et al.
Publicado: (2022)

Combinatorial Strategies With PD-1/PD-L1 Immune Checkpoint Blockade for Breast Cancer Therapy: Mechanisms and Clinical Outcomes
por: Zheng, Dan, et al.
Publicado: (2022)

PD-L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockade
por: Peng, Qi, et al.
Publicado: (2020)

The structural basis of nanobody unfolding reversibility and thermoresistance
por: Kunz, Patrick, et al.
Publicado: (2018)

Structural Basis of Nanobodies Targeting the Prototype Norovirus
por: Ruoff, Kerstin, et al.
Publicado: (2019)

PD-L1 Nanobody Competitively Inhibits the Formation of the PD-1/PD-L1 Complex: Comparative Molecular Dynamics Simulations
por: Sun, Xin, et al.
Publicado: (2018)

Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade?
por: O’Donnell, Jake S., et al.
Publicado: (2016)

Bioinformatic analysis of PD-1 checkpoint blockade response in influenza infection
por: Ou, Huilin, et al.
Publicado: (2022)

Relapsing Polychondritis following PD-1 Blockade by an Immune Checkpoint Inhibitor
por: Mutoh, Tomoyuki, et al.
Publicado: (2023)

Screening and identification of an anti-PD-1 nanobody with antitumor activity
por: Zhang, Yanting, et al.
Publicado: (2023)

Dual immune checkpoint blockade for non-small cell lung cancer patients with PD-L1 high expression: calling an end?
por: Peng, Ling, et al.
Publicado: (2021)

A Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1/PD-L1 Pathway & Translational Blockade of Immune Checkpoints
por: Li, Yongshu, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_eshf3dje8gd8oat79fp6c81g69